suloctidil and Cerebrovascular-Disorders

Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets; Catheterization; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Glomerulonephritis; Humans; Sulfinpyrazone; Suloctidil; Thiophenes; Thrombophlebitis; Thrombosis; Ticlopidine; Vascular Diseases; Vascular Surgical Procedures

Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anti-Bacterial Agents; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Humans; Mitral Valve; Platelet Aggregation; Platelet Function Tests; Pyridines; Pyridinolcarbamate; Random Allocation; Sulfinpyrazone; Suloctidil; Thiophenes; Thromboembolism; Ticlopidine

15 aged patients with clinical and laboratory evidence of cerebrovascular insufficiency and/or myocardial sclerosis were given suloctidil (Locton) at the daily dose of 200 mg X 3, for 180 days, under the conditions of an open trial. Blood and plasma viscosity, red cell deformability, total lipids, cholesterol, triglycerides, fibrinolysis (plasminogen, antiplasmin, euglobulins with and without activator, fibrinogen), and capillaroscopic parameters in the small conjunctival vessels (artery, vein, and capillary diameter, appearance of collaterals, red cell aggregation and flow homogeneity) were evaluated. After 30 days of treatment and particularly at the end of the trial a significant improvement of almost all these parameters was observed. Tolerance was always excellent.

Topics: Aged; Arteriosclerosis; Blood Viscosity; Cerebrovascular Disorders; Clinical Trials as Topic; Erythrocyte Deformability; Female; Fibrinolysis; Humans; Lipids; Male; Microcirculation; Middle Aged; Propanolamines; Suloctidil; Time Factors